Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 122, Issue 11, Pages 3931-3942Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI63170
Keywords
-
Categories
Funding
- NIH [RO1DK56223, RO1DK62324, P01HL073361]
- Genzyme (Genzyme Renal Innovations Program)
- American Heart Association [0835258N]
Ask authors/readers for more resources
DC-mediated NKT cell activation is critical in initiating the immune response following kidney ischemia/reperfusion injury (IRI), which mimics human acute kidney injury (AKI). Adenosine is an important antiinflammatory molecule in tissue inflammation, and adenosine 2A receptor (A(2A)R) agonists protect kidneys from IRI through their actions on leukocytes. In this study, we showed that mice with A(2A)R-deficient DCs are more susceptible to kidney IRI and are not protected from injury by A(2A)R agonists. In addition, administration of DCs treated ex vivo with an A(2A)R agonist protected the kidneys of WT mice from IRI by suppressing NKT production of IFN-gamma and by regulating DC costimulatory molecules that are important for NKT cell activation. A(2A)R agonists had no effect on DC antigen presentation or on Tregs. We conclude that ex vivo A(2A)R-induced tolerized DCs suppress NKT cell activation in vivo and provide a unique and potent cell-based strategy to attenuate organ IRI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available